DGAP-News

MOLOGEN AG: Start of pivotal study for cancer immunotherapy MGN1703 influences 2014 annual result

DGAP-News: MOLOGEN AG / Key word(s): Final Results
MOLOGEN AG: Start of pivotal study for cancer immunotherapy MGN1703
influences 2014 annual result

25.03.2015 / 07:00

---------------------------------------------------------------------

MOLOGEN AG: Start of pivotal study for cancer immunotherapy MGN1703
influences 2014 annual result

- Two studies with MGN1703 launched in fiscal year 2014: pivotal study in
indication colorectal cancer and phase II study in indication small
cell lung cancer

- Increase in R&D expenditure impacts annual result

Berlin, March 25, 2015 - Biotechnology company MOLOGEN is today publishing
its annual results for fiscal year 2014. The company achieved significant
progress in the ongoing development of its cancer immunotherapies. In the
past financial year, two studies were started with the lead product
candidate MGN1703: the IMPALA pivotal study in the indication colorectal
cancer and a phase II IMPULSE trial in the indication small cell lung
cancer. The net loss for the year of EUR 17.1 million was essentially
attributable to the increase in expenses for research and development (R&D)
as a result of these studies. The additional funding requirement was met by
a capital increase of around EUR 16 million carried out in February 2014.

Start of IMPALA pivotal study
In September 2014, treatment of the first patient in the phase III IMPALA
study started and further patients have since been enrolled in the study.
The trial is expected to recruit about 540 patients from more than 100
study centers in eight European countries and is being conducted in
cooperation with leading oncology experts.

"The start of the IMPALA pivotal study was a key milestone for MOLOGEN.
Patient enrollment for both this study and the IMPULSE study is now our top
priority. Our investigators are established international experts in the
field of oncology and will be providing valuable support," comments
Dr. Matthias Schroff, Chief Executive Officer (CEO) of MOLOGEN AG.

High impact at international scientific conferences
In fiscal year 2014, MOLOGEN presented a range of data on the company's
different product candidates at international scientific conferences. The
final data on the clinical phase I trial conducted in the USA confirmed the
safety and tolerability of MGN1703 and has enabled MOLOGEN to expand the